Why Phibro Animal Health is in focus after Russell index removals

Phibro Animal Health (PAHC) has come into focus after being removed from several Russell indices, including the Russell 3000E and Microcap benchmarks, a change that directly affects its index fund exposure.

These index removals can prompt mechanical buying or selling by funds that track or reference the affected benchmarks, which can influence trading volumes around the event date rather than reflecting any shift in Phibro Animal Health’s underlying operations.

For you as an individual investor, the key question is how this technical change interacts with a stock that already has a long multi year return record and currently appears relatively inexpensive on several valuation checks.

Phibro Animal Health’s share price has slipped about 44% over the past 90 days and is down 13.19% year to date. However, the 3 year total shareholder return of 135.93% and 5 year total shareholder return of 47.11% point to a strong longer term record, suggesting recent index removals and shorter term price pressure are cooling momentum rather than redefining the story overnight.

If this kind of technical selling has you thinking about where else capital might rotate, it could be a good moment to see what is moving in 18 top founder-led companies

Bulls view Phibro Animal Health’s long multi year gains and value score of 5 as an opportunity to buy on a pullback, while bears highlight index removals and recent share price pressure. Which case does the current valuation appear to support next?

Most Popular Narrative: 29% Undervalued

On the narrative view, Phibro Animal Health’s fair value of $45.60 sits well above the last close at $32.38, putting analyst expectations in sharp focus.

The company's strong recent growth is heavily dependent on the integration of the acquired Zoetis Medicated Feed Additive business and related cost synergies, which are non repeatable. Forward guidance suggests legacy product growth will slow to flat or low single digits. This implies the current trajectory of accelerating revenue and EBITDA growth is unsustainable and likely to normalize, impacting revenue and earnings growth expectations.

Analysts are building this Phibro Animal Health narrative on moderate top line assumptions, expanding margins, and a future earnings multiple that still sits below sector benchmarks. Curious which levers matter most and how they connect to that fair value gap.

Result: Fair Value of $45.60 (UNDERVALUED)

However, this Phibro Animal Health story could change quickly if regulatory pressure on antimicrobials, or faster adoption of alternative proteins, reduces the long term livestock market.

Next Steps

Given the mixed sentiment around Phibro Animal Health, with both risks and rewards in play, it is important to act promptly and evaluate the trade off yourself with 4 key rewards and 2 important warning signs

Looking for more ideas beyond Phibro Animal Health?

If Phibro Animal Health has sharpened your focus on valuation, do not stop here, fresh opportunities could be passing you by while attention stays on one stock.

• Spot potential bargains early by reviewing 44 high quality undervalued stocks before others price in their strengths.
• Secure potential income streams by scanning 9 dividend fortresses that offer substantial yields with staying power.
• Prioritize resilience by focusing on 73 resilient stocks with low risk scores that aim to keep drawdowns in check when conditions get tougher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.